News Releases

Archives: Search / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013

2012201120102009200820072003

Feb 15, 2019
Analyst conference call with urothelial cancer specialist to be held at 2:00 p.m. Pacific Time today

Nektar Therapeutics (Nasdaq: NKTR) announced today a presentation of new clinical data for bempegaldesleukin1 (NKTR-214) in combination with nivolumab in patients with first-line (1L) advanced or...

More
Feb 11, 2019

Nektar Therapeutics (Nasdaq: NKTR) announced today that it will webcast an analyst and investor conference call with a urothelial cancer specialist and company management on Friday, February 15,...

More
Dec 27, 2018

Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 37th Annual J.P. Morgan Healthcare Conference in San Francisco on...

More
Nov 14, 2018

Nektar Therapeutics (Nasdaq: NKTR) today announced the appointment of Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs. In this role, Dr. Lin...

More
Nov 9, 2018
New Efficacy, Safety and Biomarker Data Presented for Stage IV I-O Naïve Melanoma Patients in PIVOT-02 Study of NKTR-214 with nivolumab

Nektar Therapeutics (Nasdaq: NKTR) announced today a presentation of new clinical and preclinical data for its I-O pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting....

More
 

print email rss
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide